Eliminating bacterias DNA and boosting antimicrobial proteins that already exist may help prevent middle ear infections from reoccurring. These are the findings from a Nationwide Childrens Hospital study that examined how an immune defense protein common in the middle ear interacts with a structure meant to protect a colony of bacteria.
The bacterium nontypeable Haemophilus influenzae (NTHI) causes a wide range of diseases of both the lower and upper airways, including middle ear infection. NTHI, like most other bacteria, can form a biofilm, a robust community of bacteria that allows the bacteria to evade the hosts immune system and protects the bacteria from antibiotics and other therapies designed to kill them.
Human beta-defensin-3 is an antimicrobial defense protein expressed in the middle ear of humans and other mammals that kills both Gram-positive and Gram-negative bacteria. Previous research has shown that if expression of beta-defensin is disrupted, the hosts ability to control the bacteria in the upper airway is altered and infection worsens.
Investigators in the Research Institute at Nationwide Childrens Hospital hypothesized that human beta-defensin-3 might lose its power to kill NTHI if it got caught up within the extracellular DNA that makes up a biofilms outer layer, thus preventing its contact with bacteria within the biofilm.
Antimicrobial host defense proteins, like human beta-defensin-3, have been shown to bind to non-host DNA, says Lauren O. Bakaletz, PhD, director of the Center for Microbial Pathogenesis. This interaction has an impact on the defense proteins ability to function.
Upon examining their animal model of middle ear infection, Bakaletz team found that bacterial DNA and the animals defense peptides were detected together in biofilms that developed during infection. Also, the defense peptide was predominantly co-localized with the biofilms extracellular DNA.
When the team exposed the bacteria that cause ear infections to a concentration of human-beta defensin-3 that is typically detected in the a middle ear of a child with active infection, the peptide was able to kill 100 percent of the NTHI, but the killing stopped when extracellular DNA was introduced to the reaction.
These data support the conclusion that the killing activity of the antimicrobial defense protein was decreased in an NTHI-induced biofilm due to its interaction with eDNA, says Bakaletz, who is the lead study author and professor of Pediatrics and Otolaryngology at Ohio State University College of Medicine.
When they removed extracellular DNA from the biofilm, the killing activity of the defense peptide was rescued.
The ability to restore antimicrobial defense protein activity is encouraging, since biofilms are resistant to most treatments, including traditional antibiotics, says Bakaletz.
Bakaletz says this study provides evidence for a new treatment regimen to target biofilms formed by NTHI during middle ear infection. One approach would be to deliver a therapeutic agent that can disrupt bacterial DNA, in conjunction with human beta-defensin-3 to the middle ear of a child with chronic, recurrent infection. Physicians could follow the same pathway used to target the middle ear during ear tube surgery, a common treatment for chronic ear infections.
This approach would likely bolster the ability of the innate immune system to manage NTHI-induced biofilms, avoiding the need for antibiotics or empowering the use of antibiotics we already have in our arsenal, says Bakaletz. Doing so could help diminish the recurrent nature of middle ear infection.
Reference: Jones EA, McGillivary G, Bakaletz LO. Extracellular DNA within a Nontypeable Haemophilus influenzae -Induced Biofilm Binds Human Beta Defensin-3 and Reduces Its Antimicrobial Activity. J Innate Immun. 2012 Aug 22.
Source: Nationwide Children's Hospital
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.